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Lipoproteins are biochemical carriers of the insoluble lipids. They are complexes combining lipids and proteins for 
the transport of lipids. Amongst the type of lipoproteins are low-density lipoproteins (LDL) which are prevalent in 
various diseases such as obesity, diabetes, atherosclerosis, and other cardiovascular diseases (CVD). Omega-3 fatty 
acids are polyunsaturated fatty acids (PUFA) that are essential components of lipid metabolism and play a significant 
role in the human diet. Omega-3 PUFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are 
derived from fish and are necessary for proper cardiovascular functioning. Because the human body is unable to 
produce enough quantities of some omega-3, diet is an important source for its availability. When a diet is rich in 
saturated fats, the above-mentioned diseases transpire. This study investigated how consumption of two fish diets, 
Lean fish and Fatty fish, influence the lipid species of human LDL particles. The lipid species analysed in this study 
are phospholipids such as phosphatidylcholine (PC), sphingomyelin (SM), and lysophosphatidylcholine (LPC), and 
cholesteryl esters (CE), and triacylglycerols (TAG). A total of 42 volunteers with a history of impaired fasting 
glucose had randomly been divided into two groups: fatty fish (4 fish meals/week) and lean fish (4 fish meals/week) 
for 12 weeks. Blood samples had been collected from the volunteers before and after consumption of the fish meals 
and LDL particles had been isolated from the blood samples by ultracentrifugation. In this study, the lipids were 
extracted by Folch method, and the extracted lipids were analysed using Triple quadrupole mass spectrometry. The 
lipid class profile did not change due to the two fish type diets. However, the consumption of fatty fish diet increased 
the levels of lipid species of PC, LPC, and CE containing EPA and DHA acyl chains, while decreasing levels of 
several TAG species. Lean fish induced minor changes in the lipid composition of LDL particles. Based on these 
results, fatty fish diet alters the plasma LDL lipidome profile with changes induced to both the surface and the core 
composition of the LDL particles in a positive way regarding cardiovascular health. 
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n-3 polyunsaturated fatty acids (PUFAs) are dietary fats that have anti-
inflammatory properties associated with a healthy lifestyle (Swanson, Block, and 
Mousa 2012). A normal human body is unable to make enough amounts of these 
fatty acids required for lipid metabolism. Inefficient lipid metabolism creates an 
imbalance in fatty acids proportions which can cause a multitude of diseases such 
as atherosclerosis, diabetes, and other cardiovascular diseases (CVD) (Libby 
2002; Wong et al. 2013; Nascimento et al. 2018). Furthermore, atherosclerosis 
which is an inflammatory disease that occurs due to Low-density lipoproteins 
(LDL) aided accumulation of cholesterol in arteries, which leads to plaque 
formation (Libby 2002). LDLs are the carriers of insoluble lipids such as 
cholesterol and triacylglycerols (TAGs) to the plaque formation site.  
Diet is an important source for the availability of dietary fatty acids in the body. 
A lot of diet studies have been conducted to study the availability and effectivity 
of dietary fatty acids obtained from plant, and animal source (Schwab et al. 2014; 
Lesná et al. 2013). Fish is another source of n-3 PUFAs, mainly eicosapentaenoic 
acid (EPA) and docosahexaenoic acids (DHA). Both play a role in maintaining 
the viscosity of cell membranes (Conquer et al. 2000; Swanson, Block, and 
Mousa 2012) and in foetal development (Dunstan et al. 2007; Swanson, Block, 
and Mousa 2012). Most fish-based diet studies are cohort studies with fish oil 
supplements. This study was part of a randomized controlled trial conducted with 
41 volunteers for 12 weeks.  The volunteers were divided into two groups (fatty 
fish and lean fish) and were provided with four fish meals per week. This study 
was important because it allowed us to investigate the effects of fish diets on LDL 
lipid species and hypothesize the changes caused to the surface and the core 






Lipids are organic compounds present in all cells, forming a major class of 
biological molecules that include different types of fats, oils, hormones, and are 
soluble in nonpolar solvents (Muro, Atilla-Gokcumen, and Eggert 2014; Bader et 
al. 2016a). The standard classes of lipids are fatty acids, TAG, phospholipids 
(PL), and sterols (Figure 1). Series of various enzymatic steps help in the de novo 
synthesis of lipids. The synthesis starts with the production of fatty acids, which 
can convert into neutral lipids (Baenke et al. 2013). These lipids are either stored 
for use in the later stages or have the possibility of turning into signalling lipids 
like PL (Baenke et al. 2013; Bader et al. 2016b). Most of the lipids are 
hydrophobic, while some are amphiphilic. The hydrophobic lipids (non-
dissolving in water) contain hydrophobic side chains and polar head groups 
(Muro, Atilla-Gokcumen, and Eggert 2014). There is heterogeneity in lipids 
found in cells, and this diversity is contributed by the various arrangement of the 
side chains and polar head groups (Muro, Atilla-Gokcumen, and Eggert 2014). 
Recent advances in science have shown that in addition to examining 
modifications in the head groups, recognising and studying the hydrophobic side 
chains play an important part in understanding functions of lipids (Qifeng Zhang 
and Wakelam 2014; Muro, Atilla-Gokcumen, and Eggert 2014). For example, 
Atilla-Gokcumen and her research team showed that dividing HeLa cells show 
chemical specificity in the regulation of their lipid content, along with side chains 
of the lipids.  
Amphiphilic lipids are the type that has hydrophilic (dissolving in water) and fat-
loving properties and function in combination with proteins or other lipids, 
creating hurdles in the proper understanding of the functions of lipids. This has 
not stopped researchers in digging deep; various strategies have been 
implemented in identifying the lipids. They include nuclear magnetic resonance 
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(NMR), and mass spectrometry (MS), which help in detecting the lipid species 
and further understand their functions (Muro, Atilla-Gokcumen, and Eggert 
2014). Lipids can also be visualised by using fluorescent tags that work either by 
tagging the lipid itself or tagging the lipid-binding proteins (Muro, Atilla-
Gokcumen, and Eggert 2014). Amongst these methods, the most commonly used 
one is MS, where recent advances help in identifying the role of lipids using small 
amounts of the samples based on global or targeted lipid-profile analysis (Muro, 
Atilla-Gokcumen, and Eggert 2014). 
Lipid type Function/Role Structure 





































Figure 1: A modified figure showing common classes of mammalian lipids: Fatty acids (Palmitate 
(16:0)), Glycerolipids, e.g., TAG (TAG16:0, 16:1, 18:0), PL, Sterol, e.g., cholesterol, and Sphingolipid 




Lipids perform three main functions; firstly they are stored as reservoirs of fatty 
acids and sterols in an anhydrous state in lipid droplets, which have a core made 
of neutral lipids such as TAGs, to be used for membrane biogenesis (Van Meer, 
Voelker, and Feigenson 2008; Melo et al. 2011; Ruggles, Turkish, and Sturley 
2013; Bader et al. 2016b). Secondly, lipids present cell membranes the property 
of cell division and membrane trafficking via budding, fission and other types. 
These properties are provided via polar lipids that are present in the cell-matrix. 
The polar lipids have the features of self-association (via hydrophobic moieties) 
and interacting with the environment (via hydrophilic moieties) (Van Meer, 
Voelker, and Feigenson 2008). Thirdly, lipids can also participate in signal 
transduction as first and second messengers, where the degradation of polar lipids 
provides two separate parts that can be transmitted within the cell through the 
hydrophobic region and also through the cytosol via the hydrophilic part (Van 
Meer, Voelker, and Feigenson 2008). Since lipids have vast importance in all cell 
types, it has been gaining importance amongst researchers and a lot of research is 
being carried out today. 
 
The majority of the lipids (such as PL, TAG, and sphingolipids) contain both 
saturated and unsaturated fatty acids, which are also important as building blocks 
of cellular membranes (De Carvalho and Caramujo 2018). Fatty acid synthesis 
takes place in the cytoplasm of the cell from acetyl-coenzyme A (acetyl-CoA), 
Nicotinamide adenosine dinucleotide phosphate (NADPH), biotin and Mn2+, 
where acetyl-CoA is added to malonyl-coenzyme A (malonyl CoA) in a 
condensation reaction with carboxylase enzyme acting as the regulatory enzyme. 
Further elongation of the fatty acids takes place via loading of precursors to 
thioester derivatives following reduction, dehydration and another reduction 
reaction steps. β-oxidation is a catabolic process taking place in peroxisomes and 
mitochondria for the production of energy by converting fatty acids to acetyl-
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CoA and NADH through intermediate fatty acyl CoA molecules and further 
transferred to the citric acid cycle (De Carvalho and Caramujo 2018).  
 
In the de novo synthesis of fatty acids, instead of using fatty acids for energy, they 
are esterified with glycerol and sterol backbones to produce TAGs and sterol 
esters. These molecules are then stored in lipid droplets (Farese and Walther 
2009; Walther and Farese 2012; De Carvalho and Caramujo 2018). Fatty acids 
can be either saturated or unsaturated. Saturated fatty acids do not have double 
bonds between carbon atoms, while unsaturated fatty acids contain one or more 
double bonds. PUFAs have more than one double bond in their acyl chains. In 
mammals, certain PUFAs are termed as essential dietary fatty acids as they are 
important for muscle movement, inflammation and are needed from food. Some 
of the examples of important PUFAs are 20:5 n-3 EPA, and 22:6 n-3 DHA, and 
18:3 n-3 α-linolenic acid (ALA) (Monroig, Tocher, and Navarro 2013; De 
Carvalho and Caramujo 2018). Here n-3 stands for the place of a double bond, 
which is present three atoms away from the methyl end of the fatty acid. In 
humans, n-3 PUFAs are essential for various reasons (Swanson, Block, and 
Mousa 2012). The n-3 PUFAs have various mechanism of actions; they influence 
metabolites and hormone concentrations, which further affect cell and tissue 
behaviour. These PUFAs can also affect the oxidation of LDL. Human body is 
not able to synthesize these PUFAs; therefore, they need to be obtained from the 
diet either as shorter chain PUFAs such as ALA or as long-chain PUFAs like 
EPA and DHA (Beermann et al. 2003). Along with n-3 PUFAs, n-6 PUFAs are 
also important for human health. An imbalance of these fatty acids in the human 
body can influence inflammation related to multiple diseases, e.g., 
atherosclerosis, diabetes, and obesity (Weaver et al. 2009; De Carvalho and 
Caramujo 2018). It is important to have a balance between ingestion of PUFAs 
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in cells for proper homeostasis and functioning of various tissues (De Carvalho 
and Caramujo 2018).  
 
Biosynthesis of lipids takes place in many organelles; the main organelle being 
endoplasmic reticulum (ER). It is the site for the production of structural lipids 
such as PL and cholesterol as well as lipids performing non-structural roles such 
as TAG and cholesteryl esters (CE), along with ceramide, which is a precursor 
for sphingolipids (Bell, Ballas, and Coleman 1981; Van Meer, Voelker, and 
Feigenson 2008). Lipid synthesis also takes place in the Golgi apparatus and 
mitochondria. Synthesis of various sphingolipids such as sphingomyelin (SM), 
glucosylceramide, and lactosylceramide take place in the Golgi (Futerman and 
Riezman 2005; Van Meer, Voelker, and Feigenson 2008). The synthesized 
sphingolipids are exported to the plasma membrane, where they are enriched and 
packed and help resist mechanical stress (Van Meer, Voelker, and Feigenson 
2008). Plasma membrane does not take part in the lipid biosynthesis, but various 
signalling cascade reactions important for synthesis or degradation of its 
structural lipids take place (Di Paolo and De Camilli 2006; Van Meer, Voelker, 
and Feigenson 2008). In mitochondria synthesis of lysophosphatidic acid (LPA), 
a simple glycerophospholipid occurs, and it is used in the formation of TAG, 
phosphatidylglycerol and phosphatidic acid (PA) (Nagle et al. 2007; Van Meer, 
Voelker, and Feigenson 2008).  
 
Fatty acids appear in three main types of esters: PLs, TAGs and CEs. These 







Every cell in a living system has a barrier that helps keep it protected from the 
outer environment. This barrier is known as cell membrane or plasma membrane. 
The membrane forms a border around the cell keeping the cytoplasm, and various 
organelles inside the cell isolated from the outer environment and allows selected 
substances such as ions and organic molecules to pass through it making the 
barrier selectively permeable or semipermeable. The plasma membrane is 
composed of a lipid bilayer and proteins integrated into the bilayer. The lipid 
bilayer is important as it acts as a support for different proteins which are involved 
in important functions viz. signal transduction, DNA replication, protein targeting 
and cell-cell recognition (Dowhan 1997). Major components of the lipid bilayer 
are the PL, along with glycolipids and sterols. PLs are amphiphilic molecules that 
are made of a hydrophilic head part and a hydrophobic tail part (Figure 2). 
 
Figure 2: Schematic view of the PL backbone. 
PLs, are ubiquitous and are primarily present in the barrier of different cells and 
organelles in the form of the phospholipid bilayer. Depending on the polar head 
group attached to the glycerol backbone, there are different types of PL. The 
major PLs are phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI) and PA (Van Meer, Voelker, 
and Feigenson 2008). These PLs have acyl chains attached by ester bonds at the 
sn-1 and sn-2 positions of the glycerol backbone.  Most eukaryotic membranes 
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comprise at least/over 50% of PCs. As stated earlier, ER is the leading site for 
lipid biosynthesis. The PL synthesis takes place in the ER along with conjunction 
with mitochondria via mitochondria-associated membranes (Van Meer, Voelker, 
and Feigenson 2008). PA, a minor component of PLs, is the backbone for the 
synthesis of PL and TAG. Biosynthesis of PA takes place primarily in the ER. 
The synthesis starts with the addition of acyl-CoA to glycerol-3-phosphate, a rate-
limiting step, at sn-1 position by glycerol-3-phosphate acyltransferase (GPAT) to 
produce LPA. The fatty acyl-CoA added at this stage is usually saturated. Further, 
another acyl-CoA (unsaturated in this case) is added to LPA at sn-2 position by 
acylglycerol-3-acyltransferase (AGPAT) to produce PA. 
 
Following the synthesis of PAs, synthesis of PLs initiates. The biosynthesis of 
various PLs can take place via two pathways: the Kennedy pathway and cytidine 
diphosphate diacylglycerol (CDP-DAG) pathway, respectively. The two 
pathways taking place in mammals are explained in brief below. 
• Kennedy pathway: In this pathway, de novo synthesis of PE and PC takes 
place via the CDP-ethanolamine pathway and CDP-choline pathway. It 
starts with the hydrolysis of the phosphate group from the association of 
cytosolic phosphatidic acid phosphatase to PA to yield diacylglycerol 
(DAG) in the ER membrane (Gibellini and Smith 2010). DAG is used in 
the biosynthesis of both PE and PC subsequently. The CDP-
ethanolamine pathway starts with the catalysis of ATP-dependent 
phosphorylation of ethanolamine by ethanolamine kinase (EK) to 
produce phosphoethanolamine (Gibellini and Smith 2010). 
Phosphoethanolamine then reacts with cytidine triphosphate (CTP) to 
form CDP-ethanolamine via CTP: phosphoethanolamine 
cytidylyltransferase (ECT) and releases a pyrophosphate (Gibellini and 
Smith 2010). In the final step, CDP-ethanolamine attaches to the sn-3 
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position of DAG via catalysis of CDP-ethanolamine:1,2-diacylglycerol 
ethanolaminephosphotransferase and produces PE. The CDP-choline 
pathway takes place in a similar manner, with the exception of choline 
instead of ethanolamine to produce PC (Gibellini and Smith 2010). 
 
• Cytidine-diphosphate diacylglycerol (CDP-DAG) pathway: In this 
pathway, CDP-DAG synthases catalyse PA to intermediate CDP-DAG, 
which is used for the synthesis of PI, PS, and cardiolipin. In yeast, PI 
synthase Pis1 catalyses CDP-DAG to produce PI by replacing cytidine 
monophosphate (CMP) with an inositol group (Shen and Dowhan 1996; 
Tamura et al. 2013; Qiang Zhang et al. 2014). In mammals, PS is 
generated from PC and PE by PS synthases PSS1 and PSS2 which 
catalyse replacement of  choline and ethanolamine with serine (Tomohiro 
et al. 2009; Vance and Tasseva 2013; Qiang Zhang et al. 2014). 
Phosphatidylglycerol (PG) is produced by first generating precursor 
phosphatidylglycerolphosphate (PGP) by PGP synthase, which replaces 
CMP with glycerol-3-phosphate (Chang et al. 1998; Qiang Zhang et al. 
2014). Then, PGP is dephosphorylated by PGP phosphatase PTPMT1 in 
mammals to produce PG. Cardiolipin is produced via synthesis of PG and 
CDP-DAG by Cardiolipin synthase CRLS1 (J. Zhang et al. 2011; Lu et 
al. 2006; Qiang Zhang et al. 2014) 
 
1.1.2 Triacylglycerol 
TAGs are esters of glycerol attached to fatty acids where three glycerol hydroxyl 
groups are esterified. They can be either saturated (solids at room temperature) 
or unsaturated (liquids – oils at room temperature) fats. Milk has short-chain and 
medium-chain fatty acids (2-6 carbon and 8-10 carbon) (Beermann et al. 2003), 
while coconut and palm oils have medium-chain saturated fatty acids. The central 
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part of animal and plant fatty acids consumed by humans are long-chain fatty 
acids (16-22 carbon). Adipose tissue is the main site for TAG storage.  
• De novo synthesis: De novo biosynthesis is glycerol-3-phosphate pathway 
originally shown by biochemist Kennedy where PA again plays an 
important role (Wendel, Lewin, and Coleman 2010). In this pathway, 
enzyme acyl-CoA GPAT transfers the acyl group from acyl-CoA to 
position 1 of glycerol-3-phosphate (now 1-acylglycerol-3-phosphate). 
While enzyme acyl-CoA 1-acyl glycerol phosphate 2-O-acyltransferase 
(LPAT) (Coleman 2019) transfers another acyl group from acyl-CoA to 
position 2 of 1-acylglycerol-3-phosphate by catalysis forming PA. Both 
these enzymes have two isoforms each in human synthesis pathway. 
Isoforms of GPAT are present in ER (Poppelreuther et al. 2018) and the 
outer mitochondrial membrane having both their active sites facing the 
cytoplasm. Isoforms of LPAT in humans are α and β forms; α form is 
present in all tissues while the β form is predominant in ER of the cells of 
heart, liver and pancreas (Coleman 2019). PA is further catalysed by 
another enzyme called phosphatidate phosphohydrolase to form 1, 2-DAG, 
which is further catalysed by enzyme DAG transferase to form TAG. DAG 
transferase enzyme is unique to TAG synthesis, and its activity is high in 
tissues specific for TAG synthesis. 
 
1.1.3 Cholesterol and Cholesteryl esters  
Along with PLs and TAGs, sterols are essential for a eukaryotic system; one 
function being the formation of the bilayer membrane. Excess of cholesterol can 
be harmful to the cell. Therefore, excess cholesterol is esterified and stored as 
CEs in lipid droplets. Cholesterol and CEs are two forms of cholesterol that exist 
in blood plasma and are present in chylomicrons, Very Low-Density Lipoprotein 
(VLDL), Intermediate Density Lipoprotein (IDL), LDL, and High-Density 
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Lipoprotein (HDL) (Gerl et al. 2018). In mammals, synthesis of cholesterol 
(Figure 3) starts in the cytosol of the cell with the condensation of acetyl-CoA to 
β-hydroxy- β-methylglutaryl CoA (HMG CoA) by thiolase and then conversion 
of HMG CoA to mevalonate (6-carbon product) by the ER membrane protein 
HMG CoA reductase (Yeagle 1985). Mevalonate is then converted to 5-carbon 
product of isopentenyl pyrophosphate using many steps by cytosolic enzymes 
(Yeagle 1985). Subsequent reactions give rise to six isopentenyl pyrophosphates. 
Pyrophosphates condense in the next step to form squalene, a 30-carbon 
intermediate. Multiple reactions take place using enzymes bound to the ER 
membrane to convert squalene to cholesterol. Synthesis of cholesterol is tightly 
regulated in order not to have excess production. If cholesterol is produced in 
excess, it is esterified using enzyme acyl: cholesterol acyltransferase (ACAT) in 
ER membrane of intestine and liver (Yeagle 1985). The esterification takes place 
by esterifying fatty acyl CoA to a hydroxyl group of cholesterol and stored in 
lipid droplets in the cell. The proportion of sterol to sterol ester differs in different 
tissues (Yeagle 1985). Cholesterol, which is an important precursor for steroid 
hormones, is stored in esterified form in the adrenal glands (Yeagle 1985). High 







Figure 3: All the steps taking place in the synthesis of cholesterol in cytosol and ER. Excess of 
cholesterol undergoes esterification using enzyme acyl: cholesterol acyltransferase (ACAT) and is 


































1.2 Lipoproteins and lipid transport 
Lipoproteins are biochemical carriers of the insoluble lipids such as cholesterol 
and TAGs. They are complexes which combine lipids and proteins [referred to as 
apolipoproteins apo] for the transport of lipids in the body via circulation. The 
lipids in the blood are mainly fatty acyl esters. Thus, for example, cholesterol, 
which is insoluble in water, is transported via lipoproteins, which have a 
hydrophilic surface, in circulation. Lipoproteins consist of two parts; a 
hydrophobic core made of CEs and TAGs and a hydrophilic surface which 
consists of free cholesterol, PLs, and specific apolipoproteins. The lipoproteins 
play an important role in transport and absorption of dietary lipids through the 
intestine, then from liver to peripheral tissues and vice versa in a mechanism 
called reverse cholesterol transport. Classification of lipoproteins can be executed 
based on their lipid composition, size, presence of apos and density. They are of 
the following types: 
 
1.2.1 Chylomicron and Chylomicron remnants  
Chylomicrons originate from the intestine and mainly comprise of a hydrophobic 
core consisting of TAGs with small amounts of CEs and an outer membrane that 
has one copy of Apo B-48. Also, the chylomicrons contain small exchangeable 
apo, such as ApoE and ApoCs. Chylomicrons are secreted from the intestine and 
transported via the thoracic duct to the bloodstream for the transport of dietary fat 
to peripheral tissues. This transport is possible because of the exogenous pathway, 
in which lipoprotein lipase (LpL) enzyme acts on the chylomicrons and 
catabolizes hydrolysis of TAGs to fatty acids and glycerol. This process gives 
rise to chylomicron remnants (Pan and Segrest 2016). The size of chylomicrons 





After peripheral tissues remove the TAGs, the chylomicrons have CEs with a 
smaller number of TAGs. These chylomicron remnants then deliver cholesterol 
to the liver. Their size ranges from 30-80 nm. Chylomicron remnants are 
atherogenic (Barter 2014). 
 
1.2.2 Very Low-Density Lipoproteins  
VLDLs originate from the liver and are responsible for the transport of TAGs 
from the liver to the peripheral tissues. Like chylomicrons, VLDLs have a 
hydrophobic core consisting mainly of TAG with small amounts of CEs, an outer 
membrane and one molecule of Apo B-100 and small exchangeable apo. VLDLs 
are smaller in size compared to chylomicrons but, like chylomicron remnants, 
their size (range 30-80 nm) differs according to the amount of TAG present 
(Barter 2014). 
 
LpL is present at the endothelial surface of capillaries in most of the tissues in the 
body. The chylomicrons and VLDLs in plasma interact with the LpL, where LpL 
hydrolyses TAGs and releases free fatty acids which are taken up by various 
tissues as an energy source. Further, the CE transfer protein transfers CE from 
HDL to chylomicrons and VLDL (Barter 2014).  
 
1.2.3 Intermediate Density Lipoproteins 
After hydrolysis of most of their TAGs, the VLDL remnants have mainly CEs 
present in their core. They are then called as the IDLs and are in size range of 25-





1.2.4 Low-Density Lipoproteins 
LDLs have the size range from 18-25 nm. Like the other lipoproteins, LDLs have 
a hydrophobic core which mainly consists of CE and small amounts of TAG. A 
hydrophilic membrane surrounds the core showing the presence of PLs, one Apo 
B-100 molecule, unesterified cholesterol and small amounts of SMs (Figure 4). 
As shown in Figure 4 and previously explained by Esterbauer, the surface of LDL 
particle consists of approximately 700 molecules of PLs, along with one copy of 
protein Apo B-100 (Esterbauer et al. 1992). The core is composed of around 170 
molecules of TAGs, 1600 molecules of CEs, and about one-third of 600 
molecules of unesterified cholesterol (Esterbauer et al. 1992; Lund-Katz and 
Phillips 1984; Hevonoja et al. 2000). Out of the 700 molecules of PLs present in 
one particle of LDL, 450 molecules are PCs, 185 molecules are SMs, 80 
molecules are LPC, around ten molecules are of PEs. In addition, the average 
particle contains seven molecules of DAGs, and about two molecules of 
ceramides (Esterbauer et al. 1992; Sommer et al. 1992; Lalanne et al. 1999; 
Schissel et al. 1996; Amir Ravandi, Arnis Kuksis 1999; Hevonoja et al. 2000). 
Based on lipid composition present in the core and on the surface of an LDL 
particle, the particle is in a dynamic state. Therefore, there have been speculations 
whether the lipids of the core and the surface interact with each other (Ginsburg, 
Small, and Atkinson 1982; Fenske et al. 1990; Saito et al. 1996; Hevonoja et al. 
2000) or are independent (Kroon 1981; Hevonoja et al. 2000). Experiments 
conducted by Kroon using proton NMR on LDL particles indicate that the core 
lipids are in a dynamic state, i.e. the composition or structure is not constant, 
while the surface lipids remain fluid (Kroon 1981; Hevonoja et al. 2000). LpL 
interacts with chylomicrons and VLDLs by hydrolysing the TAGs via the 
exogenous pathway (Pan and Segrest 2016). About 20-60% of VLDLs is 
converted to LDL particles, with the rest being removed from the circulation to 
the liver (Pan and Segrest 2016). LDL receptors play a big role in the removal of 
LDL particles from the plasma; therefore, their expression in extrahepatic tissues 
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and particularly in the liver controls the levels of LDL in circulation. Small dense 
LDL have high retention time in the circulation. Due to their abundance, the 
small-sized LDL particles are considered pro-atherogenic compared to large LDL 
particles as they enter the arterial walls more quickly and are trapped there. This 
ability leads to them playing an important role in atherosclerosis, and their 
amount has been shown to be increased in hypertriglyceridemia, type 2 diabetes, 
and obesity (Barter 2014). 
 
Figure 4: Schematic picture of a cross-section of LDL particle indicating the main lipid types present 
on the surface and the core of the LDL particle (Hevonoja et al. 2000) 
 
1.2.5 High-Density Lipoproteins 
HDLs, like the other lipoproteins, have a hydrophobic core consisting mainly of 
cholesterol and small amounts of TAGs. The core is surrounded by a hydrophilic 
layer that is made of unesterified cholesterol, apos, and PLs (Barter 2014). HDLs 
are the smallest amongst all the lipoproteins present in plasma. Their size ranges 
from 5-12 nm, and they are also the densest lipoproteins. Apo A-I is the abundant 
structural protein present on the HDL particle surface. HDL has the possibility of 
















peripheral tissues to the liver  (Trigatti 2017). As HDL particles are 
heterogeneous, depending on their size, density, presence of apos, they can be 
further classified to very high-density HDL, large, medium, and small  HDL 
respectively (Barter 2014).  
Apos play an essential role in lipoprotein metabolism. They act as ligands for the 
binding to lipoprotein receptors, activators, or inhibitors of enzymes during the 
metabolism of lipoproteins (Wang et al. 2015). Moreover, they form a part of the 
lipoprotein outer layer and control lipid metabolism. There are different types of 






































Apo A-IV 45,000 Intestine Chylomicron, 
HDL 
Unknown 






Apo B-48 241,000 Intestine Chylomicron A structural 
protein of 
chylomicrons 




ligand of the 
LDL receptor 















Liver Lp(a) Inhibits 
plasminogen 
activation 
Table 1: Different types of Apolipoproteins. Adapted from the table of Feingold KR, Grunfeld C. 
Introduction to Lipids and Lipoproteins. [Updated 2018 Feb 2]. In: De Groot LJ, Chrousos G, Dungan 
K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available 





1.3 Low-Density Lipoprotein Metabolism 
The exogenous lipoprotein pathway initiates in the intestine. The pathway leads 
to the production of chylomicrons and chylomicron remnants (Barter 2014). 
These lipoproteins help in the organized transfer of various dietary fatty acids for 
storage and energy in muscle and adipose tissues. Chylomicrons via their 
hydrolysis and generation of chylomicron remnants allow the transport of dietary 
lipids into various tissues and the liver. There the lipids will be used for the 
formation of bile acids, VLDL and further LDL or sent back to the intestine 
(Abumrad and Davidson 2012; Hussain 2014). The endogenous lipoprotein 
pathway starts with the formation of VLDL in the liver by the transport of CEs 
and TAGs to the ER, where they are bound to Apo B-100 (Tiwari and Siddiqi 
2012). VLDL synthesis depends on the availability of TAGs. VLDL metabolism 
takes place in capillaries of peripheral tissues, where TAGs carried in VLDL are 
hydrolysed by LpL, resulting in the release of fatty acids (Dallinga-Thie et al. 
2010). The event gives rise to IDLs which are enriched in CEs and show an 
affinity for Apo E. Clearance of IDL from circulation takes place via Apo E, 
which is recognized by LDL receptor-related proteins (LRP) and mediates its 
uptake (Van De Sluis, Wijers, and Herz 2017; Dallinga-Thie et al. 2010). Only a 
small amount of IDL is cleared, and in the remaining IDL, the small percentage 
of TAGs are hydrolysed, an affinity for Apo E changes and formation of LDL 
takes place (Dallinga-Thie et al. 2010). 
 
In the liver, plasma LDL levels are controlled by the rate of VLDL production 
and the rate of LDL clearance. Various LDL receptors regulate both processes. 
The hepatic LDL receptors play an essential role in the regulation of plasma LDL 
levels. The LDL receptors partially decide the rate of production of LDL from 
VLDL in a way; for example, a decrease in IDL uptake causes low LDL receptor 
activity which increases VLDL production and vice versa (Goldstein and Brown 
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2009). Hepatocyte LDL receptor-mediated endocytosis clears 70% of the 
circulating LDL (Goldstein and Brown 2009). It undergoes in a manner that when 
there is an increase in LDL receptors, it leads to a rise in LDL clearance followed 
by a decrease in circulating LDL levels (Brown, Radhakrishnan, and Goldstein 
2018). 
 
LDL receptors have an affinity for Apo B-100 and Apo E and are responsible for 
the uptake of various lipoproteins along with LDL (Goldstein and Brown 2009). 
The regulation of LDL receptors depends on the amount of cholesterol present in 
the cell. The decrease in the levels of cholesterol allows the inactive sterol 
regulatory element-binding proteins (SREBPs), to convert to active state by 
transport from the ER to Golgi for the protease cleavage of the SREBP (Goldstein 
and Brown 2015). SREBPs are transcription factors that are important for the 
expression of LDL receptors (Goldstein and Brown 2015). Further, the active 
SREBPs are transported to the nucleus where they allow the transcription of the 
LDL receptors along with HMG-CoA reductase, a rate-limiting enzyme 
participating in the cholesterol synthesis. Conversely, high levels of cholesterol 
in the cell keeps the SREBPs in the inactive state in the ER, which does not allow 
the transcription of LDL receptors, elevating the levels of LDL particles in 
circulation (Goldstein and Brown 2009). PCSK9, a ubiquitously expressed 
protein, is also involved in controlling the amounts of hepatic LDL receptors 
(Horton, Cohen, and Hobbs 2007). When this protein binds to the LDL receptor, 
it causes its degradation of the receptor in the lysosomes and prevents the 
recycling of the receptor to the plasma membrane for the uptake of LDL particles 
(Horton, Cohen, and Hobbs 2007). Blockage of this protein by a mutation in the 
functional domain of the protein upregulates the amount of cell surface LDL 
receptors and lowers the of LDL particle concentration in plasma (Horton, Cohen, 
and Hobbs 2007). 
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1.4 Cardiovascular diseases 
CVDs are a group of diseases that are related to heart and blood vessels. Each 
disease type has a different mechanism of action. This group consists of diseases 
such as cardiomyopathy, congenital heart disease, hypertensive heart disease, 
atherosclerosis, aortic aneurysms (Nascimento et al. 2018). CVDs are the number 
one cause of mortality worldwide in men and women, accounting for about 80% 
of the deaths in middle and low-income countries (Phillips and Guazzi 2015; 
Nascimento et al. 2018). Various risk factors that play a key role in the onset of 
CVD include alcohol, unhealthy diet, obesity, high fasting plasma glucose, high 
cholesterol, diabetes, impaired kidney functions and high blood pressure (Phillips 
and Guazzi 2015). Maintaining proper lifestyle and avoiding different risk factors 













Figure 5: A) Shows the inside of a healthy artery where blood flows without any hindrance, B) shows 
deposition of cholesterol and other lipids slowly narrowing the arteries and diminishing the blood 




Atherosclerosis is a type of chronic CVD that is characterised by the deposition 
of cholesterol in large and medium-sized arteries (Figure 5). The build-up of 
atherosclerotic plaques leads to the blockage of arteries, which increases the risk 
of stroke and heart attack (Herrington et al. 2016). Depending on the arteries 
affected by the plaque formations, atherosclerosis-related diseases such as 
coronary heart disease (arteries supplying oxygen-rich blood to the hear are 
narrowed due to build-up of plaques), carotid artery disease (plaques forming in 
the carotid arteries on both sides of the neck), peripheral artery disease (plaques 
formation in arteries carrying blood to arms and legs) and chronic kidney disease 
(plaque formation in the renal arteries) has the possibility to occur 
(www.nhlbi.nih.gov/health-topics/atherosclerosis). 
 
An arterial wall is made up of three different layers, intima, media, and adventitia. 
The innermost layer, intima, is separated from circulation by a layer of 
endothelial cells, the middle layer, media, consists largely of smooth muscle cells 
and the outer layer, adventitia, of fibroblastic cells. The inner endothelial cell 
layer forms as a barrier between the blood and the arterial wall. Lipoproteins are 
normally fluxed in and out of the arterial wall. While crossing through the 
endothelial barrier, some of these ApoB-lipoproteins are retained in the arterial 
intima and accumulation of these particles is initiated along with their exposure 
to local enzymes which modify them (Tamminen et al. 1999; Carew 1989; Borén 
and Williams 2016). Inflammation and accumulation of these modified 
lipoproteins in the form of lipid droplets or vesicles in the intima mark the onset 
of atherosclerosis (Tîrziu et al. 1995; Hevonoja et al. 2000). This accumulation 
triggers the immune cells to be migrated in the intima, therefore, encountering 
the accumulated LDL particles and transforming into foam cells. The process of 
recruitment of more immune cells is started via the secretion of cytokines by the 
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transformed foam cells, which starts the process of plaque formations (Simmons 
et al. 2016). The formation of plaques is, therefore, the next step in the 
progression of atherosclerosis (Simmons et al. 2016). 
 
1.4.2 Inflammation in atherosclerosis 
In a healthy blood circulation, the arterial endothelium, which is in contact with 
the blood, does not allow the adhesion of leukocytes (Libby 2002). As mentioned 
above, the accumulation of lipids in the intima induces endothelial activation, and 
the process is initiated by recruitment of leukocytes to the intima via the 
endothelial-leukocyte adhesion molecules (Poole and Florey 1958; Libby 2002). 
One type of endothelial-leukocyte adhesion molecule that has been studied is the 
vascular cell adhesion molecule-1 (VCAM-1) which recruits leukocytes such as 
monocytes and T-lymphocytes (Figure 6) (Libby 2002). The VCAM-1 molecules 
are expressed in the parts of endothelium that are prone to lesion formation, and 
their initiation depends on inflammation inflicted by modified lipoproteins 
accumulated in the intima layer (Cybulsky and Gimbrone 1991; Libby 2002). 
Modification in lipoproteins (for example by oxidation) allows activation of the 
VCAM-1 gene mediated by nuclear factor-kB, and interleukin (IL)-1β. This 
process initiates the expression of VCAM-1 in the endothelium lesion-prone 
areas of the arteries (Collins and Cybulsky 2001; Libby 2002). 
 
On the other hand, endothelial regions prone to less atherosclerosis possess shear-
stress response elements. They are superoxide dismutase and nitric oxide 
synthase. They inhibit the VCAM-1 gene expression and hence inhibit leukocyte 
infiltration (Topper and Gimbrone 1999; De Caterina et al. 1995; Libby 2002). 
After the attachment of leukocytes to the endothelial cells, the process of 
diapedesis causes entry of leukocytes in the intima (Libby 2002). The leukocytes 
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are recruited in the intima of the arteries by various chemoattractant cytokines. 
One example of the cytokine is monocyte chemoattractant protein-1 (MCP-1) 
(Libby 2002). Research conducted in multiple laboratories shows less 
accumulation of the monocytes and lipids in MCP-1- and LDL receptor gene-
deficient mice (Gu et al. 1998; Landin Boring, Jennifa Gosling and Charo 1998; 
Libby 2002). Following the entry of the monocytes in the intima, the monocytes 
undergo morphological changes to form macrophages. The macrophages express 
scavenger receptors such as CD36 and scavenger receptor A (SRA) that take up 
the retained and accumulated modified lipoproteins (such as LDL, VLDL) to give 
rise to foam cells – a key feature of arterial lesions of atherosclerosis (Libby 
2002). Foam cells give rise to the formation of fatty streak in the affected arteries, 
which can later evolve in a complex lesion. Rupture of an atherosclerotic plaque 
then leads to clinical symptoms later in life (Libby 2002). The fatty streak 
advances to atheromas and complicated lesions via multiplication of smooth 
muscle cells, which get accumulated in plaques making the lesions bulkier. 
Formation of lesions may lead to the narrowing of the arteries causing the plaques 
to disrupt physically, which will activate thrombosis (Davies 1996; Libby 2002). 
Formation of new blood vessels from the pre-existing vasculature in angiogenesis 
and atheromas can develop in these new blood vessels as microvascular channels 
(Libby 2002). Physical disruption of plaques occurs in three different ways; 
superficial erosion of endothelial cells, disruption of microvessels formed in 
atherosclerotic plaques and a fracture in the fibrous cap of the plaques, which the 




Figure 6: Schematic figure of recruitment of monocytes to the arterial intima to form atherosclerotic 
plaques and cause inflammation. Figure adapted from(Libby 2002). 
 
 
1.5 Effect of diet  
A balanced diet is an essential aspect for a healthy lifestyle and the proper 
functioning of our body. But what defines a balanced diet? What are the elements 
to be considered for a balanced diet? There have been a lot of diet-based studies 
carried out throughout the world to understand which factors are important for 
the appropriate supply of nutrients for a healthy individual. Previous research 
shows that diets which are rich in PUFAs help reduce blood LDL levels with an 
increase in HDL levels and reach a balanced fat consumption without any harmful 
effects (Feldman 2002; Egert and Stehle 2011; Njike et al. 2015). 
 
One of the most studied diet types is the Mediterranean diet. The Mediterranean 
diet primarily consists of different fruits, vegetables, usage of olive oil, dry fruits 
(nuts), fish and limited consumption of alcohol (Widmer et al. 2015b). A 
randomized controlled trial study performed using the Mediterranean diet showed 
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patients consuming the diet had a lower number of monocytes and positive 
regulation of genes involved in LDL-oxidation in cardiovascular diseases (Trial 
et al. 2006; Salas-Salvadó et al. 2011; Widmer et al. 2015a). Fruits and vegetables 
are natural sources of various nutrients. Any type of diet suggested by 
nutritionists includes a certain amount of fruit and vegetable intake. Studies show 
that the consumption of fruits and vegetables decreases the risk of CVD because 
of the low intake of calories and also the presence of micronutrients (Widmer et 
al. 2015b). Another cross-sectional study shows that consumption of fruits and 
vegetables is associated with lower body mass index (Lin and Morrison 2002; 
Widmer et al. 2015a). A large meta-analysis study of over 200,000 patients 
showed 17% reduction of CVD in patients that were instructed to ingest three to 
four servings of fruits and vegetables every day during the study period, which 
was rechecked after two years of time period (Dauchet, Amouyel, and 
Dallongeville 2009; Widmer et al. 2015a). The American Health Association 
(AHA) and European Society of Cardiology (ESC) suggest that consumption of 
fats through the use of vegetable oils instead of saturated and trans fats as oil may 
have antioxidant properties, free radical scavengers and enzyme modulators 
(Lichtenstein et al. 2006; Graham et al. 2007; Fuhrman and Aviram 2001; 
Widmer et al. 2015a). In a crossover diet study, Marin and her group showed that 
diet rich in olive oil helps to improve endothelial function and reduce 
inflammation along with improving the endothelial progenitor cell numbers 
significant for arterial endothelial repair (Marin et al. 2011; Widmer et al. 2015a). 
In the study conducted by van Horn, the data suggest that the intake of whole-
grain foods is associated with decreased CVD morbidity and mortality by 
lowering the plasma lipid levels (Van Horn 1997; Widmer et al. 2015a). The 
AHA guidelines recommend dietary fibre intake of 25-30 g per day (Van Horn 
1997; Widmer et al. 2015a). A study conducted by Schwab and colleagues in 
2018 showed that Camelina sativa oil, a plant-based source improves the serum 
27 
 
lipid profile in subjects with impaired fasting glucose metabolism (U. S. Schwab 
et al. 2017). 
Diet studies have previously shown that walnuts are a rich source of ALA and 
have a high content of PUFAs, which have cardiovascular benefits (Feldman 
2002; Damasceno et al. 2011; Njike et al. 2015). A review article by Feldman 
suggests that eating 2-3 walnuts per day reduces total cholesterol and LDL 
cholesterol levels (Feldman 2002; Njike et al. 2015). 
 
Fish and fish oil supplements are a rich source of long-chained n-3 PUFAs and 
are consumed regularly in many countries. AHA guidelines recommend 
consumption of fish twice per week as it protects from dysrhythmia and CVD 
(Graham et al. 2007; Widmer et al. 2015a). Fish-based diet studies show that 
consumption of fish has beneficial effects on CVD and that it is associated with 
improved lipid profiles (Balk et al. 2006; Widmer et al. 2015a). Studies show that 
n-3 EPA and DHA found in fish and fish oil supplements have anti-inflammatory 
effects and that they associate with reduced risk of recurrent coronary artery 
diseases (Bouwens et al. 2009; Kris-Etherton, Harris, and Appel 2002; Swanson, 
Block, and Mousa 2012). DHA plays a vital role in the development of the foetal 
brain and eyesight (Birch and O’Connor 2001; Lyberg, Adlercreutz, and 
Adlercreutz 2005).  A large cohort study conducted in Japan comparing 
participants that have impaired glucose metabolism with normoglycemic 
participants showed that supplementing EPA to the patients having impaired 
glucose metabolism elicited lower coronary artery events compared to patients 
with impaired glucose metabolism not given EPA (Oikawa et al. 2009; Swanson, 
Block, and Mousa 2012). Consumption of fish is relatively high in the Japanese 
population, and so providing EPA treatment showed more cardiovascular benefits 




This study was part of a randomized controlled trial conducted with 41 human 
volunteers for 12 weeks. The study used samples from two fish diet groups (fatty 
fish = 20 and lean fish = 21). The aim of this study was to analyse changes caused 
to human LDL particles from consumption of these two types of fish diet. Blood 
plasma samples were collected before and after consumption of the fish diets. 
These samples were (1) analysed to study if consumption of fish diet causes any 
changes to the surface of the lipidome of LDL particle.  The samples were also 
(2) analysed to study changes caused to the composition of the core of the LDL 
particles. 
 
3 Materials and Method 
A total number of 41 volunteers with impaired fasting glucose, having body mass 
index of 25-36 kg/m2, and belonging to the age group of 43-72 years, had 
participated in a dietary study where they consumed experimental diets for 12-
weeks. This study was a part of a randomized controlled trial (U. S. Schwab et al. 
2017). The participants were randomly divided into two groups, where they were 
provided either with fatty fish diet (4 fish meals/week) or lean fish diet (4 fish 
meals/week). The volunteers were recruited in Kuopio by advertising about the 
trial in newspapers and by contacting volunteers who had previously participated 
in dietary experiments. Primary criteria for the participants were fasting plasma 
glucose concentration of 5.6-6.9 mmol/l, ≤11.0 mmol/l value of 2-h glucose 
concentration in the oral glucose tolerance test (OGTT), fasting serum total 
cholesterol concentration to be ≤7.0 mmol/l, along with LDL cholesterol and total 
TAG to be ≤5.0 mmol/l and ≤4.0 mmol/l respectively (U. S. Schwab et al. 2017). 
Blood plasma samples of 41 individuals were available for the isolation of LDL 
lipoproteins. LDL was isolated from samples that were taken before and after the 
consumption of the fish diets. Extraction of the LDL lipids was carried out using 
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the Folch method (Folch, Lees, and Sloane Stanley 1987), and the lipid species 
profiles were recorded by a triple quadrupole MS using tandem mass 
spectrometry (MS/MS) scans. The following flowchart (Figure 7) gives a brief 
overview of the experimental setup. 
Figure 7: Flow chart of the lipid analysis: I) Folch extraction of lipids, II) Mass spectrometric detection 
by employing lipid class-specific scans (e.g., CE [m/z 369] and PC [m/z 184]), III) LIMSA analysis of 
the spectral data of phosphatidylcholines, IV: Bar graph profiles treated with statistics. 
 
3.1 Extraction of Lipids 
The Folch method is a traditional and straightforward extraction method of choice 
which uses chloroform and methanol for isolation and purification of dissolved 
lipids from a sample (Folch, Lees, and Sloane Stanley 1987). It was used for the 
first time by Jordi Folch in 1957 for isolation of brain lipids from animal tissues. 
In the current experiment, the accurate volumes of the blood plasma LDL were 
recorded to be able to standardize the concentrations of the final extracts, which 
were later infused into a mass spectrometer. In the Folch extraction, the starting 
solution requires 450 µl of the aqueous solution. For example, if 190 µl of LDL 
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solution was taken into a Kimax tube, then 260 µl of millipore-quality water was 
added. Then 3 ml of methanol (M) was added, and the solution is vortexed. Next 
6 ml of chloroform (C) was added to the same solution, and the solution was 
vortexed again and kept in the dark for 30 minutes. After this incubation, the 
solution was centrifuged for 10 minutes at 3000 rpm, and the clear supernatant 
was collected into another tube. This step was performed for the complete 
removal of protein mass from the solution. Then 1.8 ml of Millipore water was 
added, and the solution was vortex mixed and centrifuged for 10 minutes at 3000 
rpm. Addition of water to the C: M containing supernatants water created a two-
phase system. The upper phase contained polar molecules and the lower phase 
the nonpolar lipids. The lower phase was transferred into another Kimax tube. 4.5 
mL of theoretical lower phase (chloroform/methanol/water, i.e. C/M/W, 86/14/1 
by vol) was added to the remaining upper phase from the original solution, and 
that solution was vortex mixed. That solution was centrifuged for the second time 
for 10 minutes at 3000 rpm, and its lower phase was transferred to the previous 
lipid extract. The upper phase was discarded. The lower phase was evaporated 
into dryness using nitrogen gas. As soon as the solution was evaporated to near 
dryness by nitrogen flow, 2 ml of C: M 1:2 solution was immediately added. 
Finally, the solution was divided into two silanized vials containing 1 ml in each 
vial and kept in -80 degree Celsius. 
 
3.2 Determination of lipid profile 
Determination of the lipid species composition in the sample extracts was 
performed by using a triple quadrupole MS (Agilent 6490 Triple Quad LC/MS 
with iFunnel technology, Agilent Technologies Inc.) (Figure 8). MS is used for 
analysing molecular based on their mass to charge (m/z) ratio. In MS, the ions are 
scanned based on their m/z ratio, and the intensity of each m/z ratio value is 




For the mass spectrometry of lipids, each stored sample was brought into room 
temperature, and a mixture with standardized liquid concentration was used to be 
infused into the MS equipment. The total volume of the solution to be infused in 
the MS equipment was 300 µl. The aliquot of the lipid extract of a sample that 
was included depended on the original volume of lipoprotein solution available 
for the lipid extraction (the more LDL added in extraction, the less extract was 
required for the infused solution). If the original volume of the LDL sample taken 
were 190 µl, then 38 µl of its lipid extract would be used, and the remaining 
would be C: M (1:2). Since the original volumes used for many of the LDL 
samples were less than 190 µl, the formula: V lipid extract = (190 µl/V original 
LDL) x 38 µl was used to calculate the accurate amount of lipid extract to be used 
for the infusion solution. After the mixing of sample extract and C: M, 4 µl of 
SPLASH LipidoMIXTM Internal Standard – [Avanti Polar Lipids, Inc., Alabaster, 
AL, USA, the components utilized for lipidome analyses were PC15:0-18:1(d7), 
PE15:0-18:1(d7), LPC18:1(d7), CE18:1(d7), TAG15:0-18:1(d7)-15:0 and 
SM18:1-18:1(d9)], 4 µl of Ceramide/Sphingoid Internal Standard Mixture I and 
20 µl of ammonium solution were added just before infusion. In the experiment, 
the samples were infused by a syringe pump into the MS equipment and passed 
through an ion source, where ionisation of the sample took place (Figure 9-1). 
The next step was passing the ions through a mass analyser, where the ions were 
scanned with MS+ scan or with specific scan modes for each lipid class. In 
precursor ion scans, all of the ions (also called precursor ions) of the sample were 
scanned, fragmented and then the fragmented ions (also called product ions) were 
selected based on lipid class-specific scans and sent to the detector for detection 
[Figure 8-(2-5)]. Precursor ion scans of m/z 184 for PC, SM, LPC, and m/z 369 
for CE were used (Brügger et al. 1997; Duffin et al. 2000). TAGs were analysed 
from the MS+ scan as ammonium adducts (Duffin, Henion, and Shieh 1991). The 
scan range was arranged to m/z 400-900 (Padro et al. 2015). Further, the mass 
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spectra of the samples were collected and analysed with statistical and 
bioinformatics tools.   
 
 
Figure 8: General schematic of triple quadrupole ESI-MS (Electrospray Ionisation Mass spectrometer). 
 
 
3.3 Data analysis and statistics 
Following the MS recording of the lipid profiles, the data were processed by 
LIMSA software (Haimi et al. 2006), which was used to identify the lipid species 
and calculate their concentrations based on the internal standards. The LIMSA 
software was running as an “add-in” in Microsoft Excel version 2003. In the 
software, there are options where the user can customize the parameters of peak 
detection depending on the spectral characteristics of the samples. Followed by 
setting these parameters, relevant lipids species, potentially available in the 
samples, were selected from the programme lipid library, and the internal 
standards were defined with their known concentrations. If a lipid species is 
missing in the database of LIMSA, there is the option to add those species 
manually through the “Compound Library” interface by telling the structure atom 
by atom. For the analysis of the data, each MS or MS/MS scan was processed 
separately and saved as an Excel file. Finally, every Excel file contained only 
certain lipid classes, which allowed to focus on and resolve the species profiles 
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each lipid class at a time. Changes within the group were analysed using paired 
Student´s t-test, and p<0.05 was regarded as statistically significant. Further fold 
change was also calculated by dividing the final relative concentration of each 
sample lipid (week 12) with the relative concentration of each sample lipid at 
baseline (week 0). 
 
4 Results 
Blood plasma-derived LDL particles from 41 individual volunteers were studied 
for lipid composition. Total of 20 individuals belonged to the fatty fish group and 
21 to the lean fish group, and they all were sampled for blood before and after 
having the experimental diets, four fish meals/per week, for 12 weeks. At first, 
lipid class profiles were studied and then the lipid species profiles in each lipid 
class were examined. When reporting the possible changes in these lipid class 
and lipid species profiles, the surface membrane lipids were addressed first and 
then the lipids in the core of the LDL particles.  
 
The LDL particles were characterized by high CE contents (group averages 
ranging between 76 and 79 mol% per total lipid), and the other major neutral lipid 
class was the TAGs (group averages 5 – 6 mol%) (Fig. 9). The main PL class was 
PC (11 – 13 mol% of total lipids), and the SM (4 – 5 mol%) and LPC (1 mol%) 
were the other detected classes. The lipid class composition of the LDL particles 
did not change due to the fatty fish or the lean fish diet (Fig. 9A, B). In addition, 
the fold change values for the major lipid classes, LPC, PC, SM, TAG and CE 
remained similar in the fatty and lean fish groups (Fig. 9C). The most evident 
change, although not statistically significant (p = 0.0512), was found for the TAG 
in the fatty fish group (Fig. 9A). The fatty fish diet decreased the proportion of 




When only the surface PLs of the LDL particles were addressed, the primary lipid 
class was PC (group averages ranging between 69 and 70 mol% per total PL), 
and the remaining marked PLs classes were SM (24 – 25 mol%) and LPC (6 – 7 
mol%) (Fig. 10). The PL class composition of the LDL particles did not change 
due to the fatty fish or the lean fish diet (Fig. 10A, B). Besides, the fold change 
values for the PL classes, PC, SM and LPC remained the same in the fatty and 







Figure 9. Lipid class profile in fatty fish (A) and lean fish (B) groups before and after the experimental 
diet and (C) the fold change (mol% after 12 weeks/mol % at day 0) in both dietary groups. Statistical 









































































Figure 10. Phospholipid class profile (LPC, PC, and SM) of LDL particle surface in fatty fish (A) and 
lean fish (B) groups before and after the experimental diet and (C) the fold change (mol% after 12 































































When the PCs of the LDL particles were addressed, the major lipid species 
observed in both the fatty fish and lean fish groups were PC 34:2 (averages 
between 27 and 28 mol% per total PC), PC 36:2 (averages between 14 and 15 
mol% per total PC), PC 34:1 (averages ranging between 13 and 15 mol% per total 
PC), PC 36:4 (averages between 8 and 8.8 mol% per total PC) PC 36:3 (averages 
between 6 and 7 mol% per total PC), and PC 38:6 (averages between 5 and 6 
mol% per total PC) (Fig. 11). In addition to the conventional acyl chains bonded 
by ester bonds, we detected a unique class of PLs called ether lipids which have 
alkyl chains attached at the sn-1 position of the glycerol backbone by an ether 
bond (marked as PC 38:6e, for example). The PC species composition of the LDL 
particles showed significant changes due to the fatty fish and the lean fish diet 
(Fig. 11A, B). In Fig. 11A, significant increase in PC species of PC 36:5 (p = 
0.0196), PC 38:6 (p = 0.0105), PC 38:6e (p = 0.0082), and PC 40:6 (p = 0.0062) 
were observed. Along with the increase in the above-mentioned PC species, a 
significant decrease was also found in PC 36:3 (p = 0.0340). The significant 
changes found in lean fish group were decreased in the mol% of species of PC 
32:1 (p = 0.0377), and PC 40:5 (p = 0.0386). Also, the fold change values for the 
PC showed changes in the fatty and lean fish groups as well (Fig. 11C). Statistical 
significances were found with increase in species PC 32:0e (p = 0.0330), PC 38:6 
(p = 0.0041), PC 40:6 (p = 0.0032), and PC 40:6e (p = 0.0098). Clear changes, 
although not statistically significant were found in two species; PC 36:5 (p = 
0.0519) and PC 38:6e (p = 0.0552) in the fold change values. 
 
Another surface lipid class of the LDL particles addressed was the SM. Major 
lipid species found in both the fatty fish and lean fish groups were SM 16:0, SM 
18:0, SM 24:1, and SM 24:2 (Fig. 12A, B). These lipid species comprised more 
than 5 mol% of total SM. The SM lipid species composition of the LDL particles 
did not change due to the fatty fish or the lean fish diet (Fig. 12A, B). Similarly, 
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the fold change values for the SM lipid species remained the same in the fatty and 
lean fish groups with minor changes (Fig. 12C). 
 
The major lipid species found in LPC class in both fatty fish and lean fish groups 
were LPC 16:0, LPC 18:0, LPC 18:1, and LPC 18:2 (Fig. 13A, B). Their 
proportions remained similar in both groups, but significant changes found were 
in minor species from the fatty fish group such as LPC 20:5 (p = 0.0295), and 
LPC 22:6 (p = 0.0387). The LPC lipid species composition of the LDL particles 
did not change due to the lean fish diet (Fig. 13B). However, a statistically 

















         
Figure 11: PC (PC = diacyl species, e = species with one acyl and one alkyl chain) species lipid profile 
in fatty fish (A), lean fish (B) groups before and after the experimental diet and (C) the fold change 
(mol% after 12 weeks/mol % at day 0) comparison of the two dietary groups. The acyl chain is 
abbreviated [chain length]: [number of double bonds]. Statistical significance (p-value in blue) refers 























































































































































































































































































































































































































































































































































Figure 12: SM species lipid profile in fatty fish (A) and lean fish (B) groups before and after the 
experimental diet and (C) the fold change (mol% after 12 weeks/mol % at day 0) comparison of the two 





























































































































































































































































































































Figure 13: LPC species lipid profile in fatty fish (A) and lean fish (B) groups before and after the 
experimental diet and (C) the fold change (mol% after 12 weeks/mol % at day 0) comparison of the two 
dietary groups. The acyl chain is abbreviated [chain length]: [number of double bonds]. Statistical 































































































































































































































































































Of the core lipids of the LDL, the major lipid species found in both fatty fish and 
lean fish in CE were CE 18:2 (averages ranging between 59 and 62 mol% per 
total CE), CE 18:1 (averages ranging between 8 and 11 mol% per total CE), CE 
20:4 (averages ranging between 9 and 10 mol% per total CE), CE 16:0 (averages 
ranging between 5 and 6 mol% per total CE), and CE 20:5 (averages ranging 
between 4 and 6 mol% per total CE) (Fig. 14). The CE species composition of 
the LDL particles showed significant changes due to the fatty fish diet (Fig. 14A). 
In Fig. 14A, significant increase in CE species CE 20:5 (p = 0.0002) was found. 
Along with the increase, significant decrease was found in species CE 16:0 (p = 
0.0439), and CE 16:1 (p = 0.0041). Also, the fold change values for the CE 
showed changes in between the fatty and lean fish groups (Fig. 14C). Statistical 
significances were found with increase in species CE 20:5 (p = 0.0004), and CE 
22:6 (p = 0.0324) in the fatty fish group. 
 
Another core lipid class studied was TAG. The major lipid species found in both 
fatty fish and lean fish were TAG 52:2 (averages ranging between 18 and 19 
mol% per total TAG), TAG 52:3 (averages ranging between 10 and 12 mol% per 
total TAG), TAG 50:2 (averages ranging between 8 and 9 mol% per total TAG), 
TAG 52:1 (averages ranging between 5 and 8 mol% per total TAG), TAG 50:1 
(averages ranging between 6 mol% per total TAG), TAG 52:4 (averages ranging 
between 5 and 6 mol% per total TAG), TAG 54:2 (averages ranging between 5 
and 6 mol% per total TAG), TAG 50:3 (averages ranging between 4 and 5 mol% 
per total TAG), and TAG 54:3 (averages ranging between 3 and 5 mol% per total 
TAG) (Fig. 15A, B). The TAG species composition of the LDL particles showed 
significant changes due to the fatty fish diet (Fig. 15A). As seen in Fig. 15A, 
significant decrease was found in minor species TAG 48:0 (p = 0.0299), and 
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major species TAG 50:2 (p = 0.0456). Besides, the fold change values for the 









Figure 14: Cholesteryl ester species lipid profile in fatty fish (A) and lean fish (B) groups before and 
after the experimental diet and (C) the fold change (mol% after 12 weeks/mol % at day 0) comparison 
of the two dietary groups. The acyl chain is abbreviated [chain length]: [number of double bonds]. 





































































































































































































































Figure 15: TAG species lipid profiles in fatty fish (A) and lean fish (B) groups before and after the 
experimental diet and (C) the fold change (mol% after 12 weeks/mol % at day 0) comparison of the two 
dietary groups. The acyl chain is abbreviated [chain length]: [number of double bonds]. Statistical 































































































































































































































































































































































































































































































The objective of this study was to determine whether two types of fish diet: fatty 
fish and lean fish alter the lipid species profile of human LDL. The main lipid 
classes analysed in this study were LPC, PC, SM, TAG, and CE. Various previous 
studies have shown that EPA and DHA are the primary n-3 PUFAs of marine 
fish, freshwater fish, and consumption of these types of fish are beneficial for a 
healthy lifestyle (Kris-Etherton, Harris, and Appel 2002; Harris, Harris, and 
Harris 1997; Oelrich, Dewell, and Gardner 2011). EPA and DHA can be 
incorporated into different lipid classes. For example, they can be incorporated 
into membrane PLs and can be used as precursors for lipid mediators having anti-
inflammatory and proresolving properties (Serhan, Chiang, and Van Dyke 2008). 
In this study, the lipid class profile did not change due to the fatty fish or the lean 
fish diet. Clear, although the not statistically significant change was found in 
TAG (p = 0.0512), with a decrease in the proportion of TAG by 19% after the 
fatty fish diet compared to the baseline values. The reduction in LDL-TAGs may 
reflect changes in TAG metabolism. Indeed, the consumption of PUFAs has been 
reported to associate with changes in the amounts of TAG in plasma. In a study 
conducted with normolipidemic individuals who were provided capsules of EPA 
and DHA, a decrease of 30% of total plasma TAGs was observed (Lindsey, 
Pronczuk, and Hayes 1992). In diet-based research conducted in 2002, in which 
42 patients with type 2 diabetes were provided with either fish oil or corn oil 
supplements, 23% decrease in plasma TAG levels due to fish oil supplements was 
shown (Petersen et al. 2002), while the group of Suzukawa found a 24% decrease 
in TAG levels in healthy individuals (Suzukawa et al. 1995). Another diet-based 
study conducted in 2011 with 42 adults with hypertriglyceridemia, showed the 
effect of fish oil supplements with a 26% decrease in total serum TAG (Oelrich, 
Dewell, and Gardner 2011). The mean plasma TAG level of the participants in 
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the fatty fish group after the intervention was reported to be decreased, albeit not 
statistically significant (Oelrich, Dewell, and Gardner 2011). 
 
There is a correlation between plasma TAG, chylomicron and VLDL levels as 
these lipoproteins are rich in TAGs (Oelrich, Dewell, and Gardner 2011). The 
concentration of TAG in lipoproteins depends on the balance between two 
factors: the rate of entry and the rate of removal of the TAGs from the plasma 
(Oelrich, Dewell, and Gardner 2011). A shift in the levels may be because of 
either of the two factors. The entry of TAG takes place at the ingestion of food, 
which is broken down and converted to free fatty acids and absorbed by intestinal 
cells and re-synthesized into TAG in chylomicrons and transported to lymphatics 
and further the bloodstream (Oelrich, Dewell, and Gardner 2011). Consumption 
of food increases the influx of TAG in blood. In this study, since the participants 
were on a fish-based diet, the amount of TAG transported to the blood might be 
reduced, which might affect the lipoprotein size. Therefore, it can be 
hypothesized that changes in the plasma TAG could affect the size of other 
lipoproteins. 
 
The complete lipid class profile of LDL surface lipids does not show any changes 
in the profiles in either the fatty fish or the lean fish group. However, analysis of 
individual lipid species shows significant changes in the lipid species profile. 
 
The PC species composition of the LDL particles showed a significant increase 
in PC species of PC 36:5, PC 38:6, PC 38:6e, and PC 40:6. PCs with five to seven 
double bonds most likely contain EPA (20:5n-3) or DHA (22:6n-3) acyl chains 
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even though the actual acyl chain composition was not determined in this study. 
Lankinen showed a substantial increase in PC 36:5, PC 38:7e and PC 40:7e in 
serum PLs after a 12-week healthy diet study containing fatty fish (Lankinen et 
al. 2011). Moreover, Ottestad observed a significant increase in plasma PC38:6 
in a study investigating the effects of fish oil supplementation on plasma 
lipidomic profiles in healthy individuals (Ottestad et al. 2012). These results are 
in line with our observations from LDL lipidome, indicating that PCs containing 
EPA and DHA acyl chains accumulate into blood components with fatty fish of 
fish oil intake. The significant changes found in the lean fish group in this study 
were a decrease in the mol% of species of PC 32:1 and PC 40:5. 
 
Previous research has shown that LPC, which is a proinflammatory lipid, plays a 
key role in various inflammatory diseases, including atherosclerosis, and diabetes 
(Schmitz and Ruebsaamen 2010; Lankinen et al. 2009). LPC alters functions of 
several cell-types such as endothelial cells, smooth muscle cells, and T-cells. 
Vasodilators such as nitric oxide are important factors that help endothelial cells 
to control smooth muscle cell tone. Evidence suggests LPC inhibit this activity 
of endothelial cells and causes vascular spasms (Takayuki Matsumoto 2007). 
Lecithin: cholesterol acyltransferase (LCAT) enzyme is a glycoprotein that is 
responsible for the formation of LPC and esterification of cholesteryl to CE by 
transferring a fatty acid from PC to cholesterol. LCAT is carried in HDL particles, 
but a small fraction also resides in LDL. Previous studies show that circulating 
LPC is associated with atherosclerosis (Orsó et al. 2015; Law et al. 2019). The 
LPC levels are increased in modified LDL, and oxidized LDL, but show an 
inverse relationship in plasma and serum in association with familial 
hyperlipidaemia and diabetes (Stübiger et al. 2012; Law et al. 2019). The topic of 
the effect of LCAT is still unclear because of many results showing increase 
LCAT activity with insulin resistance (Nass et al. 2018; Law et al. 2019), while 
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decreased LCAT activity in golden Syrian hamsters leads to atherosclerosis 
(Dong et al. 2018; Law et al. 2019). Few studies are showing the effect of diet on 
the LCAT activity; most have been conducted using rats (Romijn et al. 1998; 
Larking and Sutherland 1977). One such study conducted in humans in 2004 was 
in a French monk community where the diet cohort consisted of saturated fatty 
acids and divided into two experimental isocaloric groups; the results showed an 
increase in LCAT activity with decreasing dietary saturated fatty acids (Bérard et 
al. 2004). 
 
An increase in two of the LPC species incorporating n-3 PUFAs (LPC 20:5 and 
LPC 22:6) was found in the fatty fish diet group. Ottestad had performed a diet-
based study where healthy subjects showed an increase in the LPC species after 
intake of fish oil supplements (Ottestad et al. 2012). A study conducted by 
Lankinen and her group also showed a similar trend of increase in plasma LPC 
20:5 and LPC 22:6 after a 12-week healthy diet containing fatty fish (Lankinen 
et al. 2009). Long-chain unsaturated plasma LPC 22:6, together with TAG 58:10 
and PC 38:6, has been shown to associate with decreasing the risk of diabetes by 
the Framingham heart cohort study (Rhee et al. 2011; Ottestad et al. 2012). Per 
the results from previous research, the present study also showed a significant 
increase in plasma LPC 20:5 and LPC 22:6 due to the fatty fish diet. Based on the 
results, it can be assumed that fatty fish diet causes remodelling of the LDL 
lipidome profile in favour of more long-chained unsaturated fatty acids such as 
EPA and DHA species of LPC which have been shown to reduce inflammation 




SM is mainly secreted into circulation through VLDL and chylomicrons; major 
SM species present in these two lipoproteins are SM 16:0 and SM 18:0  (Salpeter 
and Zilversmit 1968; Nilsson and Duan 2006). The SM which is present in LDL 
and HDL are derived from the lipoproteins mentioned above after VLDL and 
chylomicrons are transported to peripheral tissues to hydrolyse. Therefore, 
finding the same species in abundance in LDL particles can be expected (Nilsson 
and Duan 2006). Major SM species found in LDL particles were SM 16:0, SM 
18:0, SM 24:1, and SM 24:2. No significant changes were found in the SM 
species profile of either the fatty fish or the lean fish group. The result of this 
study, along with another previous study conducted by Myher, shows that plasma 
SM composition is relatively stable (Myher et al. 1981). In another study, increase 
in three SM lipid species in plasma [SM(d18:0/20:0), SM(d18:0/22:6), 
SM(d18:0/26:2)] was observed in fish oil supplement group compared to high 
oleic sunflower oil group in a diet-based study conducted in healthy subjects 
(Ottestad et al. 2012). In that study, Ottestad showed that fish oil 
supplementations had no association with changes in plasma ceramides (Ottestad 
et al. 2012). In contrast, Lankinen and colleagues showed a decrease in total 
ceramide concentrations due to fatty fish consumption (Lankinen et al. 2009). 
Previous research shows the association of plasma ceramides with CVD and 
specifically linkage of high amounts of SM 24:0 to less atherogenic lipoprotein 
particles, but not less LDL in healthy subjects (Pfeiffer et al. 2001; De Mello et 
al. 2009; Hammad et al. 2010; Ottestad et al. 2012). As discussed previously, the 
main reason for the development of atherosclerosis is increased levels of LDL 
cholesterol as it leads to aggregation of the LDL particles in the arterial intima 
and stepwise modification of the LDL by various enzymes. A recent paper using 
hrSMase (human recombinant secretory sphingomyelinase) showed that an 
increased proportion of SM in LDL particles is associated with increased 
aggregation susceptibility of LDL particles and is associated with increased 
cardiovascular death (Ruuth et al. 2018). No difference in the aggregation 
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susceptibility of the LDL particles after consumption of fatty or lean fish was 
found (Manninen et al. 2019). In concordance with this finding, lipidomic 
analysis of the LDL samples performed here did not indicate any differences in 
the SM/PC ratio in the LDL particles. 
 
A study conducted by Lindsey and her group showed an increase in CE 20:5 
accompanied by a decrease in CE 18:2 with the uptake of fish oil (Lindsey, 
Pronczuk, and Hayes 1992). Two studies conducted with fish oil and fish diet 
respectively showed an increase in cholesterol concentration in small LDL 
particles with no change in the LDL size (Patti et al, 1999) and a non-significant 
increase in the concentration of small LDL predicting the probability of 
conversion of VLDL to LDL, i.e., lipolysis (Li et al. 2004). It was hypothesised 
that even though fish oil and fish diet elevated the levels of cholesterol in small 
LDL, making them dense, the effect was not sufficient enough to change the LDL 
size (Patti et al, 1999). To some extent in the present diet study, fatty fish diet 
altered LDL core composition by inducing a 1.7-fold increase in the proportion 
of CE 20:5 and 1.2-fold increase in the proportion of CE 20:6, which was 
accompanied by a decrease in CE 16:0 and CE 16:1, showing that fatty fish diet 
can change the composition of LDL particles without influencing the particle 
size. 
 
Statistically significant changes were found in TAG species profiles in the fatty 
fish group in this study. A minor TAG species TAG 48:0 and a major species 
TAG 50:2 showed a significant decrease. Fish oil supplements are shown to lower 
plasma TAG levels (Oelrich, Dewell, and Gardner 2011). One of the main results 
of Ottestad showed in their diet study that increases in plasma long-chain TAG 
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56:9 and TAG 58:10 due to intake of fish oil supplements are associated with 
reducing the risk of diabetes (Ottestad et al. 2012). Fish oil supplements also are 
shown to inhibit the synthesis of VLDL, therefore, reducing the number of plasma 
TAGs (Nestel et al. 1984; Oelrich, Dewell, and Gardner 2011). A decrease in 
TAG 48:1, TAG 48:2, and TAG 50:2 were seen with n-3 fish oil supplements in 
a 24-week weight loss in obese women (McCombie et al. 2009). Similarly, a 
decrease in TAG 48:1 and TAG 48:2 which was observed in a knock-out mouse 
model of PPARg2−/− Lepob/Lepob (Peroxisome proliferator-activated receptor-
gamma), which is essential for the development of adipose tissues (Medina-
Gomez et al. 2007) showing a selective modification of TAGs in obesity and 
type-2 diabetes (McCombie et al. 2009). Compared to these studies, the present 
study showed a decrease in only TAG 50:2, which can be hypothesised to play 
role in lowering the risk of obesity, for example. Previous dietary interventions 
show a significant increase in long-chain polyunsaturated TAGs with fish 
consumption for eight weeks and lean fish but not fatty fish (Lankinen et al. 2009; 
Ottestad et al. 2012). Whereas no significant changes were found in the TAG 
species profile of the lean fish group. 
 
A three-layer model (consisting of outer surface layer, interfacial layer, and the 
core) for LDL particle in terms of the proper orientation of the PL at the surface 
to the completely random orientation of the core lipids has been proposed (Saito 
et al. 1996; Deckelbaum, Shipley, and Small 1977; Hevonoja et al. 2000). 
According to this model, the lipid classes in LDL particles are not homogeneously 
distributed, and the dynamic state of the particles contributes to the change in the 
structure of the particles along with a change in the composition of the lipids 
(Hevonoja et al. 2000). It might be one reason for the alterations in some of the 
surface as well as core lipids of the LDL particles. Rhee et al. showed that LC-
MS based lipid profiling could be used for the identification of the relationship 
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between the lipid acyl chain and the double bond content and the risk of disease 
(Rhee et al. 2011). Selective modifications such as an increase in the TAG and 
PL species having long-chain highly unsaturated fatty acids of high carbon 
number lay behind the potential positive effect of fish oil supplements (Ottestad 
et al. 2012). 
 
6 Conclusion 
The lipid class profile did not change due to the two fish type diets. The lipid 
classes that mainly contributed to the changes in the LDL lipidome profiles in 
this study were PC, LPC, CE, and TAG. The consumption of fatty fish diet 
increased the levels of lipid species of PC, LPC, and CE containing EPA and 
DHA acyl chains, while decreasing levels of two TAG species. Elevated levels of 
PC 38:6 and LPC 22:6 were shown to help in decreasing the risk of diabetes by 
the Framingham heart cohort study (Rhee et al, 2011; Ottestad et al. 2012). 
Elevated levels of the same species were also observed in the present study 
indicating to some degree that fish diet is one of the essential facets in the 
reduction of risk of diabetes. Although the composition of core CEs increased in 
certain species, the overall CE composition remained unchanged. The present 
study did not show any changes in the SM species, which can indicate that fish 
diet specifically n-3 PUFAs from fish, might not have any effect in altering the 
composition of SM in the lipidome. There are various pharmacological agents 
such as niacin and fenofibrate, in the market already used for the reduction of 
TAG (Ford et al, 2002; Oelrich, Dewell, and Gardner 2011). This study, along 
with others, shows that diet containing fatty fish can decrease short-chain TAGs 
of plasma LDL, and provide another potential approach that could be beneficial 
than consuming medicines. Lean fish induced minor changes in the lipid 
composition of LDL particles. In this study, a moderate sample size was studied, 
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which included middle-aged volunteers with impaired fasting glucose. The 
results acquired from this study could be limited to this age group. Further 
investigations of the effect of fish diet might be imperative with larger sample 
size and different age groups. In conclusion, fatty fish diet alters the plasma 
lipidome profile and the changes induced to both the surface and the core lipid 
composition of the LDL particles may affect the physical properties of the LDL 
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